Lyell Immunopharma Inc. logo

Lyell Immunopharma Inc.

LYEL | NASDAQ
Chart Builder DCF Calculator
$11.15
+$0.22 (+2.01%)
Sep 22, 2026, 12:13 PM ET · Market open

Market Data

Market Cap
$267.83M
Enterprise Value
$100.66M
Beta
-0.07
Average Volume
152.67K
Shares Outstanding (Diluted)
23.36M
Shares Change YoY
57.94%
Institutional Ownership
54.74%
Exchange
NASDAQ
ISIN
US55083R2031

Price Performance

Price Change 1M
-30.0%
Price Change 3M
-13.5%
Price Change 6M
-45.7%
Price Change YTD
-62.3%
Price Change 1Y
-17.0%
Price Change 3Y
-62.6%
Price Change 5Y
-95.5%
1M CAGR (ann.)
-25.7%
1Y CAGR (ann.)
-13.5%
5Y CAGR (ann.)
-49.1%
All-Time CAGR
-47.9%

Valuation

PE Ratio
-0.93
Forward PE
N/A
PEG Ratio
0.01
Forward PEG
-0.14
PS Ratio
9,919.73
Forward PS
23,731.40
PB Ratio
1.15
P/FCF Ratio
-1.55
P/Adj. FCF Ratio
-1.26
P/OCF Ratio
-1.92
EV/Sales
3,728.32
EV/EBIT
-0.49
EV/EBITDA
-0.51
EV/FCF
-0.58
Earnings Yield
-107.7%
FCF Yield
-64.4%
Adj. FCF Yield
-79.2%

Financial Health

Net Cash
$167.17M
Total Debt
$36.93M
Cash & Short-Term Investments
$204.1M
Total Assets
$311.15M
Current Ratio
5.36
Quick Ratio
5.36
Debt / Equity Ratio
0.16
Debt / EBITDA
-0.19
Debt / FCF
-0.21
OCF / Debt
-4.65
Interest Coverage
0.00
Altman Z-Score
-7.01
Piotroski F-Score
2

Margins & Profitability

Gross Profit Margin
-8537.0%
Operating Profit Margin
-542522.2%
EBITDA Margin
-885037.0%
Net Profit Margin
-920285.2%
FCF Margin
-639148.2%
Adj. FCF Margin
-785918.5%
SBC / Revenue
130863.0%
SBC Impact (per share)
-23.0%

Returns

Return on Assets
-79.9%
Return on Equity
-91.6%
Return on Invested Capital
-70.8%
Return on Capital Employed
-70.8%
Return on Tangible Assets
-79.9%

Historical Growth (CAGR)

Revenue CAGR 3Y
-91.8%
Revenue CAGR 5Y
-68.3%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
-99.1%
EPS CAGR 5Y
-67.2%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-4.0%
FCF CAGR 5Y
2.0%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
7
EPS Growth Next 3Y
23.8%
Revenue Growth Next 3Y
1740.5%
Earnings Date
Nov 9, 2026
EPS Estimate (next Q)
-$2.06
EPS Growth Est (next Q)
-3.3%
Revenue Est (next Q)
$3.83K
Revenue Growth Est (next Q)
-74.5%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$42.67
Price Target Upside
290.4%

Cash Flow

Operating Cash Flow
$-171.77M
Free Cash Flow
$-172.57M
Adj. Free Cash Flow
$-212.2M
FCF Per Share
-$5.73
OCF Per Share
-$5.70
OCF/S Ratio
-493555.6%

Income Statement

Revenue
$27K
Gross Profit
$-2.31M
Operating Income
$-146.48M
EBITDA
$-198.19M
Net Income
$-248.48M
EPS (Diluted)
-$11.77
Revenue / Employee
$167.70
Profit / Employee
$-1.54M
Employees
161

© 2026 bestshares.com. All rights reserved.